At SciRhom, we are leveraging our world-leading expertise on the TACE/ADAM17 signalling pathway and its central role in the development of autoimmune diseases and other pathologies to develop innovative biopharmaceuticals. We are pursuing proprietary and novel therapies targeting iRhom2 and accelerating our lead antibody programme SR-878 towards clinical development and beyond.
